Study of Efficacy and Safety of MAS825 in Patients With COVID-19

NCT04382651 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Pneumonia, Impaired Respiratory Function

Interventions

DRUG: MAS825
OTHER: Placebo
DRUG: Standard of Care (SoC)

Sponsor

Novartis Pharmaceuticals